WO2020144588A1 - Compositions for treatment of the menopause, osteopenia and osteoporosis, and menopause/related metabolic and vascular disorders - Google Patents

Compositions for treatment of the menopause, osteopenia and osteoporosis, and menopause/related metabolic and vascular disorders Download PDF

Info

Publication number
WO2020144588A1
WO2020144588A1 PCT/IB2020/050111 IB2020050111W WO2020144588A1 WO 2020144588 A1 WO2020144588 A1 WO 2020144588A1 IB 2020050111 W IB2020050111 W IB 2020050111W WO 2020144588 A1 WO2020144588 A1 WO 2020144588A1
Authority
WO
WIPO (PCT)
Prior art keywords
ferula
extract
menopause
extracts
compositions according
Prior art date
Application number
PCT/IB2020/050111
Other languages
French (fr)
Inventor
Ezio Bombardelli
Elena LOMBARDO
Giuseppe TRUNFIO
Original Assignee
Herbal E Antioxidant Derivatives S.R.L. Ed In Forma Abbreviata H&Ad S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Herbal E Antioxidant Derivatives S.R.L. Ed In Forma Abbreviata H&Ad S.R.L. filed Critical Herbal E Antioxidant Derivatives S.R.L. Ed In Forma Abbreviata H&Ad S.R.L.
Publication of WO2020144588A1 publication Critical patent/WO2020144588A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Definitions

  • the present invention relates to compositions useful for treatment of the symptoms of the menopause, comprising extracts of plants with oestrogenic activity optionally combined with other medicinal plant extracts, vitamins and oligoelements.
  • the symptoms associated with the menopause which may be neurovegetative (hot flushes, sweating, headache) or psychiatric (irritability, depression, sleep disorders), and osteoporosis, which frequently arises during the menopause, are known to be attributable to oestrogen deficiency. Hormone replacement therapy is therefore an effective therapeutic remedy.
  • phytoestrogens i.e. heterocyclic compounds contained in legumes and cereals which have a structure resembling that of oestradiol
  • Diet supplementation with soya derivatives or administration of phytoestrogens derived from soya consequently represents a promising alternative to oestrogen administration.
  • Soya is the main oestrogen source currently used; soya isoflavones have a well- established oestrogen-like activity, which is particularly effective against osteoporosis, due to its inhibiting action on tyrosine kinase which in turn inhibits osteoclastic activity, with a consequent increase in bone mineral density, and against post-menopausal symptoms, especially in reducing hot flushes, nervousness, headaches and palpitations.
  • Cimicifuga racemosa black cohosh
  • the roots and rhizome of Cimicifuga contain formononetin, an oestrogen, in addition to triterpene glycosides.
  • the extract generally titrated in triterpene glycosides with values ranging between 0.5 and 30%, has proved effective in the treatment of menopause-related neurovegetative disorders and dysmenorrhoea [E. Ducker et al, Planta Med., 57 (1991) 420]
  • EP1200107 and EP0847755 disclose the use of Cimicifuga extracts as alternatives to hormone replacement therapy.
  • US6267994 discloses the use of the extract, combined with compounds having anti-oestrogen activity, especially tamoxifen, for the treatment of oestrogen-dependent tumours.
  • WO 201307807 describes the use of Cimicifuga racemosa extracts for the prevention and treatment of osteoporosis.
  • KR20020037292 discloses phytoestrogen compositions based on Ferula tenuisecta extract.
  • Cimicifuga racemosa extract reduces the classic symptoms of the menopause, such as hot flushes, sweating, insomnia and anxiety, as from the first administrations.
  • Said combination has surprisingly exhibited a synergic effect between the two ingredients, with a considerably greater activity than that obtained from the simple sum of the individual ingredients.
  • the invention therefore provides compositions containing a Cimicifiiga racemosa extract and a Ferula sp extract.
  • Water-alcohol extracts available on the market from a number of sources, are preferred.
  • a further aspect of the invention also relates to the use of the compositions to treat pre-menopause, menopause and post-menopause symptoms.
  • the Ferula species which can be used according to the invention comprise Ferula sumbul (also known as Ferula moschata ), Ferula hermonis and Ferula communis.
  • Ferula sumbul extract is particularly preferred.
  • the weight ratio of Cimicifuga racemosa extract to Ferula sumbul extract can range from 1 :2 to 1 : 10, preferably from 1 :3 to 1 :7, and is more preferably 1 :5.
  • the unit doses in oral compositions typically range from 10 to 100 mg for the Cimicifuga extract and 20 to 1000 mg for the Ferula extract.
  • compositions according to the invention can be administered orally in the form of tablets or cellulose or gelatin capsules, or topically, using suitable excipients.
  • the compositions according to the invention are prepared by conventional techniques, such as those described in Remington’s Pharmaceutical Handbook, Mack Publishing Co., N.Y., USA.
  • the Ferula extracts contain substances which interact with the oestrogen receptors and inhibit the proliferation of ovarian and breast cancer cells, while the Cimicifuga racemosa extracts contain both bisdesmosidic saponins with oestrogenic activity (cimigenol glucosides) and other saponins which, after elimination of the glucoside residue from the C22 position, give rise to the formation of compounds with a spirostane structure having progestinic activity.
  • the Cimicifuga racemosa extracts also contain vitamin K2, which plays an important part in osteogenesis, together with vitamin D (Abstracts of Papers, 253rd ACS National Meeting & Exposition, San Francisco, CA, USA, April 2-6, 2017 (2017), CHED-526).
  • Vitamin K2 regulates the calcium metabolism responsible, and contributes to maintaining the bone mass.
  • the Cimicifuga and Ferula extracts can be advantageously combined with oligoelements, vitamins, in particular vitamin D and vitamin B complex, lipoic acid and/or one or more phytotherapeutic extracts, as additional ingredients to supplement the beneficial properties of the compositions.
  • Vaccinium myrtillus or Vaccinium macrocarpon extracts containing pentacyclic triterpenes and procyanidins A and B, improve the vascular function of menopausal women suffering from cardiovascular damage associated with excess weight, characteristic of the menopause, and from problems associated with the symptoms of metabolic syndrome and type 2 diabetes; the intake of antioxidants and alpha-glucosidase and alpha amylase enzyme inhibitors in the intestine gives rise, in addition to body weight modulation, to an improvement in endothelial function and normalisation of the lipid parameters, with a particular increase in HDL cholesterol and a reduction in blood glucose levels.
  • compositions according to the invention may also contain Citrus bergamia and Cynara cardunculus var sylvestris extracts, described in IT RM2007A000515; EP 2364158; and WO 2010 554920.
  • Examples of other extracts useful for the purposes of the invention are Olea europaea, Ginkgo biloba, Citrus aurantium var. bergamia, Citrus reticulata var clementine, Salvia officinalis, Vitis vinifera (seed) and Berberis aristata extracts.
  • Said extracts have a high content of polyphenols which perform a powerful action against free radicals, as well as inhibiting enzymes such as alpha-amylase, glucosidase and lipase in the intestine.
  • the lipophilic diterpenes present in Salvia officinalis extract such as carnosol, carnosic acid and the like, cross the blood-brain barrier, wherein they exert an anti- inflammatory and neuroprotective activity with favourable effects on the neurovegetative and vascular disorders frequent in the menopause.
  • Olea europaea leaf extracts contribute to the reduction of osteopenia and osteoporosis as a result of synergic effects between verbascoside, oleuropein and the pentacyclic triterpenes ursolic and oleanolic acid.
  • adaptogenic plant extracts can be added.
  • the preferred adaptogenic plant extract is Withania somnifera , which contains withanolides, active ingredients having a powerful inhibitory effect on acetyl and butyryl cholinesterase, enzymes involved in the brain function.
  • the products were administered to normal women and those at the start of surgical menopause after cessation of the menstrual cycle, the patients being monitored in a randomised trial according to the methods and criteria of conventional protocols such as the Greene scale.
  • the patients were treated for 1 month with two capsules a day, morning and evening, containing 20 mg of Cimicifuga racemosa water-alcohol extract, 100 mg of Ferula sumbul , or a combination of the two in the same quantitative ratio.
  • Table 1 shows the data relating to the doses normally used for Cimicifuga racemosa and Ferula sumbul extracts, with the results expressed as the total scores obtained on the Greene scale.
  • Table 2 shows the data produced with the Greene scale referring to the scores of
  • Example 1 Soft gelatin capsules containing Cimicifuga racemosa and Ferula 1:5 extracts
  • Example 2 Hard gelatin capsules containing Cimicifuga racemosa and
  • Example 3 Tablets containing Cimicifuga racemosa and Ferula 1:5 extracts for the treatment of osteoporosis
  • Example 4 Tablets containing Cimicifuga racemosa and Ferula 1:5 extracts for the treatment of cognitive impairment
  • Example 5 Tablets containing Cimicifuga racemosa and Ferula 1:5 extracts for the treatment of metabolic and cardiovascular disorders.
  • the Ferula extract (0.1-10 uM; 20% ferutinin), incubated with neurones co-cultured with human astrocytes according to the scheme shown in Figure 1, stimulates constitutive nitric oxide synthase (cNOS) in astroglial cells and increased expression of the enzyme glutamine synthase, and this effect is followed by glutamate release from the neurones and astrocytes (Table 1). Surprisingly, this effect was three times greater when the Ferula extract (10 uM) was added to the co-cultures ( Figure 2, Table 3). In fact, Cimicifuga alone did not influence cNOS or glutamate release from the cell culture.
  • cNOS constitutive nitric oxide synthase
  • Cimicifuga unexpectedly inhibited inducible NO synthase (iNOS), which is known to depress constitutive release of NO, thus increasing the effect of ferutinin on glutamate release ( Figure 2, Table 3).
  • iNOS inducible NO synthase

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed are compositions comprising Cimicifuga racemosa and Ferula extracts and optionally other phytotherapeutic extracts, vitamins and oligoelements. The compositions described are useful in the treatment of menopause symptoms..

Description

COMPOSITIONS FOR TREATMENT OF THE MENOPAUSE. OSTEOPENIA
AND OSTEOPOROSIS. AND MENOPAUSE-RELATED METABOLIC AND
VASCULAR DISORDERS
The present invention relates to compositions useful for treatment of the symptoms of the menopause, comprising extracts of plants with oestrogenic activity optionally combined with other medicinal plant extracts, vitamins and oligoelements.
State of the art
The symptoms associated with the menopause, which may be neurovegetative (hot flushes, sweating, headache) or psychiatric (irritability, depression, sleep disorders), and osteoporosis, which frequently arises during the menopause, are known to be attributable to oestrogen deficiency. Hormone replacement therapy is therefore an effective therapeutic remedy.
However, oestrogen administration is not risk-free, especially in the long term, due to the possible onset of oestrogen-dependent tumours; the administration of oestrogen-like substances of plant origin known as phytoestrogens, i.e. heterocyclic compounds contained in legumes and cereals which have a structure resembling that of oestradiol, is therefore preferable. Diet supplementation with soya derivatives or administration of phytoestrogens derived from soya consequently represents a promising alternative to oestrogen administration.
Soya is the main oestrogen source currently used; soya isoflavones have a well- established oestrogen-like activity, which is particularly effective against osteoporosis, due to its inhibiting action on tyrosine kinase which in turn inhibits osteoclastic activity, with a consequent increase in bone mineral density, and against post-menopausal symptoms, especially in reducing hot flushes, nervousness, headaches and palpitations.
Cimicifuga racemosa (black cohosh), a plant belonging to the Ranunculaceae family, is another source of phytoestrogens; the roots and rhizome of Cimicifuga contain formononetin, an oestrogen, in addition to triterpene glycosides. The extract, generally titrated in triterpene glycosides with values ranging between 0.5 and 30%, has proved effective in the treatment of menopause-related neurovegetative disorders and dysmenorrhoea [E. Ducker et al, Planta Med., 57 (1991) 420] EP1200107 and EP0847755 disclose the use of Cimicifuga extracts as alternatives to hormone replacement therapy.
US6267994 discloses the use of the extract, combined with compounds having anti-oestrogen activity, especially tamoxifen, for the treatment of oestrogen-dependent tumours.
The association of formononetin with other phytoestrogens such as those derived from soya, namely genistein and daidzein, was described for the same use in US5830887, and for the treatment of premenstrual syndrome and menopausal syndrome. EP 1321149 discloses combinations of Cimicifuga racemosa extracts with adaptogenic plant extracts.
WO 201307807 describes the use of Cimicifuga racemosa extracts for the prevention and treatment of osteoporosis.
KR20020037292 discloses phytoestrogen compositions based on Ferula tenuisecta extract.
Although the formulations described to date provide safe, effective alternatives to hormone treatment, they do not control chronic disorders of multifactorial origin, such as the multiple degenerations associated with the menopause and aging. Metabolic syndrome, osteoporosis and neurological problems are normally present in many post menopausal patients, and therefore require therapeutic approaches based on different action mechanisms in order to slow the progress of the main pathological manifestations.
Description of the invention
It has now surprisingly been found that the combination of a Cimicifuga racemosa extract with a Ferula sp extract reduces the classic symptoms of the menopause, such as hot flushes, sweating, insomnia and anxiety, as from the first administrations. Said combination has surprisingly exhibited a synergic effect between the two ingredients, with a considerably greater activity than that obtained from the simple sum of the individual ingredients.
In a first aspect thereof, the invention therefore provides compositions containing a Cimicifiiga racemosa extract and a Ferula sp extract. Water-alcohol extracts, available on the market from a number of sources, are preferred.
A further aspect of the invention also relates to the use of the compositions to treat pre-menopause, menopause and post-menopause symptoms.
The Ferula species which can be used according to the invention comprise Ferula sumbul (also known as Ferula moschata ), Ferula hermonis and Ferula communis. The Ferula sumbul extract is particularly preferred.
The weight ratio of Cimicifuga racemosa extract to Ferula sumbul extract can range from 1 :2 to 1 : 10, preferably from 1 :3 to 1 :7, and is more preferably 1 :5.
The unit doses in oral compositions typically range from 10 to 100 mg for the Cimicifuga extract and 20 to 1000 mg for the Ferula extract.
The compositions according to the invention can be administered orally in the form of tablets or cellulose or gelatin capsules, or topically, using suitable excipients. The compositions according to the invention are prepared by conventional techniques, such as those described in Remington’s Pharmaceutical Handbook, Mack Publishing Co., N.Y., USA.
The Ferula extracts contain substances which interact with the oestrogen receptors and inhibit the proliferation of ovarian and breast cancer cells, while the Cimicifuga racemosa extracts contain both bisdesmosidic saponins with oestrogenic activity (cimigenol glucosides) and other saponins which, after elimination of the glucoside residue from the C22 position, give rise to the formation of compounds with a spirostane structure having progestinic activity. The Cimicifuga racemosa extracts also contain vitamin K2, which plays an important part in osteogenesis, together with vitamin D (Abstracts of Papers, 253rd ACS National Meeting & Exposition, San Francisco, CA, USA, April 2-6, 2017 (2017), CHED-526). Vitamin K2 regulates the calcium metabolism responsible, and contributes to maintaining the bone mass. In the compositions according to the invention, the Cimicifuga and Ferula extracts can be advantageously combined with oligoelements, vitamins, in particular vitamin D and vitamin B complex, lipoic acid and/or one or more phytotherapeutic extracts, as additional ingredients to supplement the beneficial properties of the compositions. For example, Vaccinium myrtillus or Vaccinium macrocarpon extracts, containing pentacyclic triterpenes and procyanidins A and B, improve the vascular function of menopausal women suffering from cardiovascular damage associated with excess weight, characteristic of the menopause, and from problems associated with the symptoms of metabolic syndrome and type 2 diabetes; the intake of antioxidants and alpha-glucosidase and alpha amylase enzyme inhibitors in the intestine gives rise, in addition to body weight modulation, to an improvement in endothelial function and normalisation of the lipid parameters, with a particular increase in HDL cholesterol and a reduction in blood glucose levels.
Alternatively or additionally, the compositions according to the invention may also contain Citrus bergamia and Cynara cardunculus var sylvestris extracts, described in IT RM2007A000515; EP 2364158; and WO 2010 554920.
Examples of other extracts useful for the purposes of the invention are Olea europaea, Ginkgo biloba, Citrus aurantium var. bergamia, Citrus reticulata var clementine, Salvia officinalis, Vitis vinifera (seed) and Berberis aristata extracts. Said extracts have a high content of polyphenols which perform a powerful action against free radicals, as well as inhibiting enzymes such as alpha-amylase, glucosidase and lipase in the intestine.
Extracts of Olea europaea leaves, Vaccinium myrtillus, Vaccinium macrocarpum and Salvia officinalis , as well as containing high percentages of chlorogenic acids and flavonoids, also contain ursane and oleanane triterpenic acids, which act as immune system modulators and enzymatic regulators of protein synthesis.
The lipophilic diterpenes present in Salvia officinalis extract, such as carnosol, carnosic acid and the like, cross the blood-brain barrier, wherein they exert an anti- inflammatory and neuroprotective activity with favourable effects on the neurovegetative and vascular disorders frequent in the menopause.
Olea europaea leaf extracts contribute to the reduction of osteopenia and osteoporosis as a result of synergic effects between verbascoside, oleuropein and the pentacyclic triterpenes ursolic and oleanolic acid.
To counteract symptoms such as anxiety, depression, cognitive and memory impairment, adaptogenic plant extracts can be added. The preferred adaptogenic plant extract is Withania somnifera , which contains withanolides, active ingredients having a powerful inhibitory effect on acetyl and butyryl cholinesterase, enzymes involved in the brain function. Withania somnifera extracts having a withanolide content ranging between 4 and 12%, preferably about 8%, optionally combined with a phospholipid mixture containing 20% phosphatidylserine, are preferably used.
The amounts of said additional ingredients can vary within a wide range, determined by the skilled person on the basis of the common general knowledge available in the literature.
Pharmacological trial
The synergy of Cimicifuga racemosa and Ferula sumbul extracts has been demonstrated in clinical trials using the Greene parametric scale (Greene, JG. Measuring the symptom dimension of quality of life: General and menopause-specific scales and their subscale structure. In: Hormone replacement therapy and quality of life. The Parthenon Publishing Group. (Edited by: Schneider HPG) Boca Raton, London, New York, Washington. 2002: 35-43).
The products were administered to normal women and those at the start of surgical menopause after cessation of the menstrual cycle, the patients being monitored in a randomised trial according to the methods and criteria of conventional protocols such as the Greene scale. The patients were treated for 1 month with two capsules a day, morning and evening, containing 20 mg of Cimicifuga racemosa water-alcohol extract, 100 mg of Ferula sumbul , or a combination of the two in the same quantitative ratio. Table 1 shows the data relating to the doses normally used for Cimicifuga racemosa and Ferula sumbul extracts, with the results expressed as the total scores obtained on the Greene scale.
Table 1
Figure imgf000007_0001
Table 2 shows the data produced with the Greene scale referring to the scores of
10 patients per group with analysis of the individual parameters examined.
Table 2
Figure imgf000007_0002
The data obtained demonstrate that the combination of the two extracts as a whole is markedly superior. Parameter-by-parameter analysis clearly demonstrates that individual symptoms characteristic of the menopause are reduced by up to 90% after a few days’ treatment.
The examples below further illustrate the invention.
Example 1 - Soft gelatin capsules containing Cimicifuga racemosa and Ferula 1:5 extracts
Figure imgf000008_0001
Example 2 - Hard gelatin capsules containing Cimicifuga racemosa and
Ferula 1:5 extracts
Figure imgf000008_0002
Example 3 - Tablets containing Cimicifuga racemosa and Ferula 1:5 extracts for the treatment of osteoporosis
Figure imgf000008_0003
Example 4 - Tablets containing Cimicifuga racemosa and Ferula 1:5 extracts for the treatment of cognitive impairment
Figure imgf000009_0001
Example 5 - Tablets containing Cimicifuga racemosa and Ferula 1:5 extracts for the treatment of metabolic and cardiovascular disorders.
Figure imgf000009_0002
Example 6 - Tablets containing Salvia officinalis and Ferula extracts 1:1
650 mg soft gelatin capsules
Figure imgf000009_0003
Example 7- Synergic effect of Cimicifuga racemosa and Ferula sumbul extract on glutamate release from astrocyte and neurone co-cultures
The Ferula extract (0.1-10 uM; 20% ferutinin), incubated with neurones co-cultured with human astrocytes according to the scheme shown in Figure 1, stimulates constitutive nitric oxide synthase (cNOS) in astroglial cells and increased expression of the enzyme glutamine synthase, and this effect is followed by glutamate release from the neurones and astrocytes (Table 1). Surprisingly, this effect was three times greater when the Ferula extract (10 uM) was added to the co-cultures (Figure 2, Table 3). In fact, Cimicifuga alone did not influence cNOS or glutamate release from the cell culture.
However, Cimicifuga unexpectedly inhibited inducible NO synthase (iNOS), which is known to depress constitutive release of NO, thus increasing the effect of ferutinin on glutamate release (Figure 2, Table 3). Table 3
Figure imgf000010_0001
The clear synergic effect between Cimicifuga and Ferula found for glutamate release is also correlatable with synergic effects in clinical practice, as known, for example, from Na-Ra Han et al, Nutrition Research 35(2015, 774-783; Xi-Dan et al, Phytomedicine, 63(2019) 153012.

Claims

1. Compositions comprising an extract of Cimicifuga racemosa and an extract of Ferula sp.
2. Compositions according to claim 1 wherein the extract of Ferula sp. is an extract of Ferula sumbul, Ferula hermonis or Ferula communis.
3. Compositions according to claim 1 wherein the extract of Ferula sp. is an extract of Ferula sumbul.
4. Compositions according to any one of claims 1 to 3 wherein the extracts of Cimicifuga and Ferula are water-alcohol extracts.
5. Compositions according to claims 3 and 4 wherein the weight ratio of extract of Cimicifuga racemosa to extract of Ferula sumbul is 1 :5.
6. Compositions according to any one of claims 1 to 5 further comprising at least one of the extracts of Olea europaea, Citrus bergamia, Vaccinium myrtillus, Vaccinium macrocarpum, Cynara cardunculus var sylvestris, Ginkgo biloba, Citrus aurantium var. bergamia, Citrus reticulata var clementine, Withania somnifera, Salvia officinalis, Vitis vinifera and Berberis aristata.
7. Compositions according to any one of claims 1 to 6 further comprising alpha-lipoic acid and/or vitamin D and/or vitamins of the B group and/or oligoelements.
8. Compositions according to claims 1 - 7 for use in the treatment of pre-menopause, menopause and post-menopause symptoms.
PCT/IB2020/050111 2019-01-10 2020-01-08 Compositions for treatment of the menopause, osteopenia and osteoporosis, and menopause/related metabolic and vascular disorders WO2020144588A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102019000000343 2019-01-10
IT102019000000343A IT201900000343A1 (en) 2019-01-10 2019-01-10 COMPOSITIONS FOR THE TREATMENT OF MENOPAUSE, OSTEOPENIA AND OSTEOPOROSIS, METABOLIC AND VASCULAR DISORDERS RELATED TO CLIMATER

Publications (1)

Publication Number Publication Date
WO2020144588A1 true WO2020144588A1 (en) 2020-07-16

Family

ID=66286581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/050111 WO2020144588A1 (en) 2019-01-10 2020-01-08 Compositions for treatment of the menopause, osteopenia and osteoporosis, and menopause/related metabolic and vascular disorders

Country Status (2)

Country Link
IT (1) IT201900000343A1 (en)
WO (1) WO2020144588A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115403658A (en) * 2022-05-19 2022-11-29 首都医科大学 Arbuterol-Tyr-Gly-Phe-Gly-Gly, synthesis, activity and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346267B1 (en) * 2000-07-07 2002-02-12 Wakunaga Of America Co., Ltd. Composition and method for treatment of symptoms associated with insufficient estrogen production
WO2009121600A2 (en) * 2008-04-04 2009-10-08 Lachifarma S.R.L. Laboratorio Chimico Farmaceutico Salentino Hydroxytyrosol formulations for the treatment and prevention of dna oxidative damages in post-menopausal conditions
US20120071501A1 (en) * 2001-09-19 2012-03-22 Bionorica Ag Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones
WO2015089489A1 (en) * 2013-12-13 2015-06-18 Requis Pharmaceuticals Inc. Antihistamines in combination with a range of substance for improved health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40792E1 (en) 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
DE19652183C1 (en) 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Treating oestrogen-dependent tumour with Cimicifuga racemosa extract
DE60022517T2 (en) 1999-07-15 2006-08-03 Kobenhavns Universitet COMPOSITION WITH STEORIDISH ESTROGEN EFFECT WITHOUT INCREASING BREAST CANCER RISK
KR20020037292A (en) 2000-11-13 2002-05-18 권승룡 Composition of phytoestrogens for hormone replacement therapy including the treatment of menopausal women
ITMI20012678A1 (en) 2001-12-18 2003-06-18 Marfarma S R L COMPOSITIONS FOR THE RELIEF OF THE SYMPTOMS OF THE CLIMATE SYNDROME
DE102008056745A1 (en) 2008-11-11 2010-05-12 Continental Automotive Gmbh Device for controlling a vehicle function and method for updating a control device
IT1392535B1 (en) 2008-11-17 2012-03-09 Herbal & Antioxidant Derivatives S R L In Forma Abbreviata H&Ad S R L FITOCOMPLESS FROM FRUIT OF BERGAMOTTO, PREPARATION PROCEDURE AND USE AS A FOOD AND PHARMACEUTICAL SECTOR.
WO2013007807A1 (en) 2011-07-12 2013-01-17 Bionorica Se Selected cimicifuga fractions for the treatment of osteoporosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346267B1 (en) * 2000-07-07 2002-02-12 Wakunaga Of America Co., Ltd. Composition and method for treatment of symptoms associated with insufficient estrogen production
US20120071501A1 (en) * 2001-09-19 2012-03-22 Bionorica Ag Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones
WO2009121600A2 (en) * 2008-04-04 2009-10-08 Lachifarma S.R.L. Laboratorio Chimico Farmaceutico Salentino Hydroxytyrosol formulations for the treatment and prevention of dna oxidative damages in post-menopausal conditions
WO2015089489A1 (en) * 2013-12-13 2015-06-18 Requis Pharmaceuticals Inc. Antihistamines in combination with a range of substance for improved health

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
APPENDINO GIOVANNI ET AL: "Daucane phytoestrogens: a structure-activity study", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, vol. 65, no. 11, 1 November 2002 (2002-11-01), pages 1612 - 1615, XP002763459, ISSN: 0163-3864 *
CARLA PALUMBO ET AL: "Influence of ferutinin on bone metabolism in ovariectomized rats. I: role in preventing osteoporosis", JOURNAL OF BONE AND MINERAL METABOLISM, SPRINGER-VERLAG, TO, vol. 27, no. 5, 31 March 2009 (2009-03-31), pages 538 - 545, XP019742506, ISSN: 1435-5604, DOI: 10.1007/S00774-009-0070-X *
EDEN J A: "HERBAL MEDICINES FOR MENOPAUSE: DO THEY WORK AND ARE THEY SAFE?", MEDICAL JOURNAL OF AUSTRALIA, AUSTRALIAN MEDICAL PUB., SYDNEY, AU, vol. 174, no. 2, 15 January 2001 (2001-01-15), pages 63/64, XP008015045, ISSN: 0025-729X *
STAFF UHN: "Newly Discovered Alpha Lipoic Acid Benefits", 17 January 2017 (2017-01-17), pages 1 - 4, XP055626091, Retrieved from the Internet <URL:https://universityhealthnews.com/daily/bones-joints/newly-discovered-alpha-lipoic-acid-benefits/> [retrieved on 20190925] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115403658A (en) * 2022-05-19 2022-11-29 首都医科大学 Arbuterol-Tyr-Gly-Phe-Gly-Gly, synthesis, activity and application thereof
CN115403658B (en) * 2022-05-19 2024-04-23 首都医科大学 Ursolic acid-Tyr-Gly-Phe-Gly-Gly, synthesis, activity and application thereof

Also Published As

Publication number Publication date
IT201900000343A1 (en) 2020-07-10

Similar Documents

Publication Publication Date Title
Amalraj et al. Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: a review
Ahmed et al. Ginsenoside Rb1 as a neuroprotective agent: A review
Kolodziejczyk-Czepas Trifolium species–the latest findings on chemical profile, ethnomedicinal use and pharmacological properties
US7338672B2 (en) Herbal supplement for cognitive related impairment due to estrogen loss
Provino The role of adaptogens in stress management
US6346267B1 (en) Composition and method for treatment of symptoms associated with insufficient estrogen production
Sabouri-Rad et al. Ginseng in dermatology: a review
Manouchehri et al. Polycystic ovaries and herbal remedies: A systematic review
US20090155388A1 (en) Weight phyto-nutraceutical synergistic composition
Kassis et al. Efficacy and safety assessments of Ferula assa-foetida L., traditionally used in Greco-Arab herbal medicine for enhancing male fertility, libido and erectile function
WO2020144588A1 (en) Compositions for treatment of the menopause, osteopenia and osteoporosis, and menopause/related metabolic and vascular disorders
WO2021064132A1 (en) Treatment of menopausal syndrome and/or symptoms associated with menopause
Ayameang et al. Anti-inflammatory activity and quantitative analysis of major compounds of the mixtures of Derris scandens (DZSS) formula
RU2485965C2 (en) Compartment-specific dual combination of herbal extracts of ginkgo biloba and ginseng
Perry et al. Adaptogens
US20090274780A1 (en) Menopause treatment composition and regimen
EP1502597A1 (en) Compositions for the treatment of anxiety and associated disorders
Roychoudhury et al. Herbal aphrodisiac biomolecules in the management of male reproductive and sexual problems: connecting nature with clinics
KR101791574B1 (en) Pharmaceutical composition for preventing or treating female menopausal disorder comprising an extract of black rice aleurone layer
Martellet et al. New opportunities for the application of natural products based on nitric oxide modulation: From research to registered patents
van Die Phytotherapeutic treatments for menopause related symptoms
Muralidhara et al. Multiple broad spectrum Neuromodulatory effects of Bacopa monnieri and Centella asiatica: mechanistic considerations
Anastassakis Panax Ginseng (Korean or Asian Ginseng)
Govindaraj et al. Botanicals in Alleviating Menopause
Anastassakis A Few More and Recently Reported Herbs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20703512

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20703512

Country of ref document: EP

Kind code of ref document: A1